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Abstract
Polymerase chain reaction (PCR) detection has become the gold standard for
diagnosis and typing of enterovirus (EV) and human parechovirus (HPeV) infections.
Its effectiveness depends critically on using the appropriate sample types and high
assay sensitivity as viral loads in cerebrospinal fluid samples from meningitis and
sepsis clinical presentation can be extremely low. This study evaluated the sensitivity
and specificity of currently used commercial and in‐house diagnostic and typing
assays. Accurately quantified RNA transcript controls were distributed to 27
diagnostic and 12 reference laboratories in 17 European countries for blinded
testing. Transcripts represented the four human EV species (EV‐A71, echovirus 30,
coxsackie A virus 21, and EV‐D68), HPeV3, and specificity controls. Reported results
from 48 in‐house and 15 commercial assays showed 98% detection frequencies of
high copy (1000 RNA copies/5 µL) transcripts. In‐house assays showed significantly
greater detection frequencies of the low copy (10 copies/5 µL) EV and HPeV
transcripts (81% and 86%, respectively) compared with commercial assays (56%,
50%; P = 7 × 10−5). EV‐specific PCRs showed low cross‐reactivity with human
rhinovirus C (3 of 42 tests) and infrequent positivity in the negative control (2 of
63 tests). Most or all high copy EV and HPeV controls were successfully typed (88%,
100%) by reference laboratories, but showed reduced effectiveness for low copy
controls (41%, 67%). Stabilized RNA transcripts provide an effective, logistically
simple and inexpensive reagent for evaluation of diagnostic assay performance.
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The study provides reassurance of the performance of the many in‐house assay
formats used across Europe. However, it identified often substantially reduced
sensitivities of commercial assays often used as point‐of‐care tests.
K E YWORD S
enterovirus, enterovirus A71, parechovirus, PCR, RNA transcripts
1 | INTRODUCTION
Enteroviruses (EVs) belonging to the family Picornaviridae are
currently classified into 116 serologically distinct enterovirus types,
which can be assigned into four genetically distinct species, HEV‐A to
D1,2 and over 250 human rhinovirus (HRV) types divided into three
species (A‐C). Species B EV types including echoviruses and coxsackie
B viruses (CBVs) are the most frequently identified viral causes of
meningitis and other central nervous system (CNS)‐associated
infections in western countries, while the species A serotype,
EV‐A71 is an important cause of hand, foot, and mouth disease and
encephalitis in South‐East Asia and EV‐D68 within species D has
recently emerged as a respiratory pathogen occasionally leading to
acute flaccid myelitis (AFM).3 Infections with human parechoviruses
(HPeVs) in the genus Parechovirus are enteric, usually asymptomatic
apart from those of HPeV type 3, which is associated with sepsis‐like
illness, meningitis, and encephalitis in young children.4-6
Although there is no effective antiviral treatment available for EV
infections, detection and identification of EV and HPeV infections are
vital for informing other treatment options, supportive care and
prognosis of affected individuals. The reverse‐transcriptase polymer-
ase chain reaction (RT‐PCR) is now the “gold standard” for diagnosing
EV and HPeV infections due to its advantages of fast turn‐around
time and high sensitivity over virus isolation.7 Even in severe cases,
viral loads are relatively low in cerebrospinal fluid (CSF) samples that
are typically tested in patients presenting with meningitis or
encephalitis, and may be missed by less sensitive methods.
To detect all EV types, RT‐PCR assays for the detection of EV
RNA usually target the highly conserved 5′ non‐translated region
(5′NTR). Depending on the primer and probe design, some molecular
detection methods may fail to detect certain EV types such as
EV‐D68, whereas some assays may also detect HRVs (reviewed in
Holm‐Hansen3). EV and HPeV serotypes are defined serologically
and genetically by their capsid region sequences; virus typing,
therefore, requires amplification and sequencing of regions within
this structural gene block, typically VP1.8,9
Evaluation of sensitivity and specificity of the diagnostic assays
used for EV and HPeV detection and typing is essential. We have
previously evaluated the use of RNA transcripts of several EV and
HRV serotypes and HPeV1 for quality control purposes in six expert
clinical virology laboratories in Europe.10 Following this study, we
have now produced a further set of RNA transcript standards for
selected representative serotypes from EV species A‐D and HPeV3.
The RNA standards were distributed via the European non‐polio
enterovirus network (ENPEN) to members in diagnostic and
reference laboratories for evaluation of the sensitivity of their
routinely used assays for detection and typing of enteroviruses.
2 | MATERIALS AND METHODS
2.1 | RNA transcript synthesis
Available full‐length cDNA clones of EV species A (EV‐A71
genogroup B4 strain, accession number AF316321)11, B (Bastianni
prototype strain of echovirus 30 [E30], AF162711), C (Coe strain of
coxsackivirus A 21 [CVA21], D00538), and D (Fermon strain of
EV‐D68, NC_038308), and parechovirus (HPeV3, GQ18302612) were
selected for this study. For rhinovirus species C (HRV‐C49,
MF775365), a partial 5′‐UTR‐VP4‐VP2 clone was assembled from
amplified sequences. All plasmids were transformed into DH5α
competent cells by heat shock, with single colonies picked and grown
in liquid medium before plasmid extraction using the QIAprep Spin
Miniprep Kit (Qiagen), according to the manufacturer’s instructions.
Plasmids were linearized at the 3′ end, and RNA transcripts were
produced using the MEGAscript T7 Transcription Kit (Ambion),
followed by DNase treatment to remove template DNA. RNA was
purified using the RNAEasy Mini Kit (Qiagen), according to the
manufacturer’s instructions.
2.2 | RNA quantification and stability assessment
Quantification of RNA transcripts was carried out using the
NanoDrop ND‐1000 UV‐Vis Spectrophotometer (Thermo Fisher
Scientific) and the Qubit 4 Fluorometer (Thermo Fisher Scientific).
The concentrations obtained were used to calculate copy numbers of
transcripts produced, assuming a mean molecular mass for each base
of 330 g/mol. A serial dilution of RNA transcripts (105 to 10−1
copies/µL) was prepared using the RNA storage solution (Thermo
Fisher Scientific; 1 mM sodium citrate, pH 6.4) containing herring
sperm carrier RNA (50 µg/mL) and RNasin (New England BioLabs UK,
100 U/mL). Dilutions were aliquoted and stored at −80°C before
testing and distribution to the participating laboratories.
EV species A (EV‐A71) and C (CVA21) transcripts were
investigated for stability at different temperatures. Transcripts
were incubated in storage solution for up to 30 days at
ambient temperature, 4°C and 37°C. A further aliquot of each was
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freeze‐thawed three times. The amount of RNA was quantified by
RT‐PCR and values compared to those of the original preparations.
2.3 | Transcript amplification by real‐time RT‐PCR
For quantification of RNA sequences before distribution, In‐house
quantitative real‐time RT‐PCR was carried out using the StepOne-
Plus Real‐Time PCR System (Thermo Fisher Scientific), according to
the manufacturer’s instructions. The following reaction conditions
were used: 50°C for 30minutes, 95°C for 15minutes followed by 45
cycles of 95°C for 10 seconds then 60°C for 1minute. A total of
20 μL reaction volume containing 2 μL of the diluted transcript was
used. PCRs used primers and probes as previously described for
EV,13 HRV,14 and HPeV15 (Table S1).
2.4 | Laboratory evaluation
RNA from EV species A‐D and HPeV was distributed in 200 μL volumes
of storage buffer at concentrations of 10 and 103 copies/5 μL. The HRV
species C, as a negative transcript control, was distributed only at the
higher concentration (103 copies in 5 μL) to investigate cross‐reactivity
of EV assays with rhinoviruses. Storage buffer was included as another
negative transcript control. Sample labeling was coded, and the details
of coding were provided to participating laboratories only after all
results were received. Coded transcript panels were sent by standard
registered post to the participating laboratories in February 2019.
2.5 | Participating laboratories
The RNA transcripts were distributed via ENPEN to member diagnostic
and reference laboratories for evaluation of the sensitivity of their
routinely used assays for detection and typing of EV and HPeV.
Laboratories were identified by a standardized code (L1, L3….). Coded
transcripts panels were shipped by standard registered UK post in
February 2019. Participating labs were asked to test 5ul of each sample
sent using their routine detection and/or typing assay. Results were
reported through an EU survey tool (https://ec.europa.eu/eusurvey/
runner/ENPEN_transcript_study_panel_A_2019). Collected information
comprised the results of testing in terms of positivity or negativity, Ct
values were obtained, virus type and further technical information such
as volume tested, extraction method (if used) and additional information
on the testing methods used (listed in Supplementary Methods).
3 | RESULTS
3.1 | Validation of the transcript panel
RNA concentrations of EV‐A71, E30, CVA21, EV‐D68, HPeV3,
and HRV‐C49 transcripts were determined by two different
physicochemical methods (Nanodrop and Qubit). The values obtained
by the two methods' values were similar (within a factor of two in all
cases; data not shown) and the mean value was used for calibration.
Serial dilutions of each RNA transcript ranging from 104 to 10−1
copies in 5 µL were assayed in replicate by quantitative EV and HPeV
RT‐PCR assay. Amplification was highly reproducible between
replicates and between transcripts of different EV species and
HPeV3 (Figure 1). All samples were positive with an input of 10
copies, while detection of single copies of RNA was stochastic
(2/5 replicates detected). The end‐point detection of the RNA
transcripts and their similarity in Ct values to each demonstrates
that quantitation was reproducible between the transcripts of the
five different viral species (all Ct values were within a factor of two
from each other), Finally, the measured gradients of the lines of best
fit between log viral load and Ct‐value were between 3.1 and 3.6,
consistent with efficient amplification.
To investigate the stability of RNA transcript, two representative
EV transcripts (EV‐A71 and CVA21) were subjected to a range of
temperatures and freeze‐thaw cycles and their RNA content was
assessed by real‐time PCR (Figure 2). No or minimal changes in Ct
values (reflecting residual RNA concentrations) were observed on
freezing‐thawing or incubation for up to 30 days at 4°C or ambient
temperate, while there was an approximately 10‐fold reduction in
RNA levels on incubation at 37°C for 30 days No decline in Ct values
was observed for any transcript stored at 4°C or room temperate
F IGURE 1 Quantitative RT‐PCR of RNA transcripts of different
EV species, HRV and HPeV. Ct values of replicate dilutions of EV,
HRV and HPeV RNA transcripts used in the evaluation panel; data
points indicate mean values of 3 technical replicate; error bars show
standard errors of the mean. EV, enterovirus; HPeV, human
parechovirus; HRV, human rhinovirus; RT‐PCR, reverse‐
transcriptase polymerase chain reaction
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over the month period, providing reassurance that transcripts
received by the participating laboratories were not degraded.
A panel of 12 RNA transcripts was constructed containing two
concentrations of EV‐A71, E30, CVA21, EV‐D68, and HPeV3 (10 and
1000 copies in 5 µL), HRV‐C49 (1000 copies in 5 µL) and a water
control. These panels were sent to the participating laboratories
using standard registered post at ambient temperature; delivery
times ranged from one to 4 weeks providing reassurance for the RNA
quality.
3.2 | Participating laboratories
A total of 39 laboratories from 17 European countries including
Belgium (number of participating laboratories = 1), Cyprus (1),
Denmark (1), France (1), Finland (4), Germany (2), Greece (1), Italy
(2), Ireland (1), Netherlands (1), Norway (3), Slovenia (1), Spain (3),
Sweden (3), and UK (14) participated to this study. From these, 12
were classified as national reference laboratories and the remaining
27 as primary diagnostic laboratories (Table S2).
Most laboratories (n = 36) participated in the evaluation of
detection assays, some evaluating multiple assays; this produced a
total of 63 sets of results for detection assays. Reference
Laboratories showed greater investment in in‐house detection
methods for EV and HPeV detection; in‐house assays were used
for 19 of the 22 results sets provided by 12 reference laboratories
for the study (86%), with only one reference laboratory located
within a local hospital contributing results from three different
commercial assays). This compares 29/41 (71%) of in‐house result
sets provided by 27 diagnostic laboratories. Commercial kits used
included assays from BioMérieux, Seegene, Progenie, Luminex, Fast
Track Diagnostics, Elite Ingenius, Biofire, Altona, and AusDiagnostics
(Table 1).
A total of 37 sets of in‐house typing results were provided, from
these 18 sets (14 for EV typing, 3 for HPeV, and 1 for both) were
reported by reference laboratories and 12 sets by diagnostic
laboratories from 7 different countries including Spain, Sweden,
Greece, Italy, Germany, Norway, and UK. Most of these results were
reported for EV typing (n = 29) but HPeV typing was also
performed (n = 10).
3.3 | Sensitivity and specificity of screening
methods
The sensitivity and specificity of detection assay results were
calculated, and totals adjusted for the declared target range of the
tests. Intended assay targets included combined EV and HPeV
detection (n = 23), EV detection only (n = 17), HPeV detection only
(n = 10) and combined EV and HRV detection (n = 7) as well as mono‐
specific assays for EV‐D68 (n = 1) and EV‐A71 (n = 1). Two HRV‐only
assays were evaluated for specificity only.
In general, laboratories reported high rates of detection (98% for
CVA21; 100% for EV‐A71, E30, and EV‐D68) of the EV transcripts at
the higher concentration (103 RNA copies in 5 µL) (Figure 3). More
variable detection of the low concentration transcripts (10 RNA
copies in 5 µL) was reported, ranging from 62% (EV‐D68) to 90%
(EV‐A71). Detection frequencies of the HPeV3 transcripts were
comparable; 97% for higher concentration and 75% for lower
concentration. For assays reporting Ct values for the higher and
lower concentration transcripts, values were compared to evaluate
viral load ratios (Figure S1). Although no assay produced quantitative
results, reported results showed a 58 to 106 fold differences in
geometric mean viral loads, close to the expected 100‐fold
difference. Assays were therefore reasonably quantitative in relative
terms in this concentration range.
Assays were also generally highly specific, with only 2 high Ct
value (weak positive) results reported falsely positive from the 62
tests performed. A larger number of tests specific for EVs reported
HRV detection, with five tests designed for the detection of EV
(n = 2), EV and HPeV (n = 2) and EV‐D68 (n = 1) reporting positive
results with the HRV‐C49 RNA transcript.
Methodology differences contributed substantially to the sensi-
tivity of the screening assays (Figure 3B). In particular, commercial
assays, often highly multiplexed for other viral targets in CSF,
showed significantly reduced sensitivity for the detection of RNA
transcripts at a lower concentration compared to in‐house methods
F IGURE 2 Stability of RNA transcripts on incubation at different
temperatures and freeze/thawing. Fold changes in RNA detection of
two representative RNA transcripts preparations of CAV21 (EV
species C) at low copy number and EV‐A71 (species A, high copy
number) used for laboratory distribution. Transcripts were incubated
for various durations at different temperatures. Detected viral loads
were compared to those of RNA transcripts stored at −80°C. RNA
transcripts were additionally subjected to three freeze/thaw cycles
(rapid cooling and thawing; right hand panel). Bar heights show fold
reductions of RNA relative to the starting amount; error bars show
SEMS of three assay repeats
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(56% detection rate compared to 81%; P = .0009; Figure 3B). There
was a comparable difference in HPeV detection rates, with 50% of
the lower concentration transcript detected by commercial and 86%
by in‐house assays. There were significant differences in assay
sensitivity in results reported by diagnostic and by reference
laboratories (Figure 3C). This is largely accounted for by the greater
use of in‐house assays by reference laboratories.
Commercial assays included a variety of platforms and assay
specificities (Table 1); several including Biofire, AusDiagnostics,
Progenie and some assays from Seegene and bioMérieux were
unable to detect the lower concentration RNA control (10 RNA
copies in 5 µL), and in some cases, even the higher concentration
RNA transcript (1000 copies in 5 µL) (Biofire, AusDiagnostics). We
further investigated the sensitivity of the Biofire assay with
intermediate RNA concentrations; assay sensitivity lay between
400 and 1000 RNA copies for most of the EV transcripts and
between 1000 and 40 000 copies for HPeV RNA (Table 2).
3.4 | Sensitivity and accuracy of EV and HPeV
typing methods
EV and HPeV typing performed by 22 participating laboratories were
based upon amplification by PCR and Sanger sequencing of VP1 and/
or VP3/VP1 (EV) or VP3/VP1 (HPeV) regions either using species‐ or
genus‐specific assays. Half of the typing was performed at the
reference laboratories and half at the diagnostic laboratories
resulting in the use of 37 different typing assays (Figure 4). The
higher concentration EV RNA transcripts were successfully typed by
88% of reference laboratories (45 of 51) and 71% of diagnostic
laboratories (36 of 57; P = .02 by Fisher’s Exact Test) whereas the
lower concentration EV transcripts were successfully typed by 41%
of reference laboratories (21 of 51) and 31% of diagnostic
laboratories (16 of 51; P = 0.2). High concentration HPeV RNA
transcripts were successfully typed by all reference (3 of 3) and
diagnostic laboratories (6 of 6) but one of each failed detection of the
low copy HPeV transcript.
4 | DISCUSSION
This study describes a quality control exercise for EV and HPeV
detection and typing in 43 virus diagnostic and reference labora-
tories in 17 European countries. Intrinsic to the study design was the
use of stabilized RNA transcripts of representative serotypes and
species of EV and HPeV.
4.1 | The suitability of RNA transcripts for quality
assurance
RNA transcripts were used to evaluate the sensitivity and specificity
of commercial and in‐house detection and characterization assays for
EVs and HPeV. Multiple EV types were used in the panel to estimate
the range of serotypes and species that could be detected;
enteroviruses are substantially diverse genetically, and conserved
TABLE 1 Testing results from individual commercial assay platforms
Detection1
Manufacturer Assay Ct 10 1000 HRV‐C
Enterovirus assays
Altona RealStar Y 4/4 4/4 P
BioMerieux Enterovirus R Y 4/4 4/4 N
EV/HPeV assays
Ausdiagnostics Resp. viruses 16‐well N 0/5 4/52 N
Ausdiagnostics Viral 8‐well version 3.0 N 2/5 5/5 N
Ausdiagnostics Viral 8‐well version 01 N 1/5 4/52 N
Biofire Film array ME panel v1.4 N 0/5 4/53 N
Elite‐Ingenious Meningitis viral 2 MGB panel Y 4/5 5/5 N
Fast Track FTD Viral Meningitis Y 5/5 5/5 N
Fast Track FTD Neuro 9 Y 5/5 5/5 N
Luminex NxTAG Resp. Pathogen Panel Y 5/5 5/5 N
Progenie Real Cycler EVPA ‐ Version 4 Y 2/5 4/4 N
Progenie Real Cycler Monotest Y 1/5 5/5 N
HRV/RV assays
BioMerieux Rhino/Entero R gene Y 1/3 ‐ P
Seegene Allplex Resp. Panel 2‐ RP9802x Y 1/4 3/3 N
Seegene Allplex Resp. Panel RV16 Y 3/4 4/4 P
Parechovirus assays
BioMerieux Parechovirus r‐gene Y 1/1 1/1 N
1Detection frequencies in the 10 and 1000 copies/5 µL transcript dilutions. Insensitive results—low detection rate of the 10 copy/5 µL control—are
underlined, unexpected results—detection failure of 1000 copy/5 µL controls are indicated in bold.
2The 1000 copy/5 µL E30 (EV species B) transcript was undetected in both assays.
3The 1000 copy/5 µL HPeV3 transcript was undetected.
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regions of the genome between EV species suitable for amplification
by PCR are largely confined to short motifs in the 5′‐UTR.13 EV and
HPeV RNA transcripts possess a number of attributes that make
them suitable as reagents for quality assurance (QA) and evaluation
of diagnostic assays. Most importantly, their content can be
quantified in absolute terms, so it is possible to express assay
sensitivities in terms of RNA copies. This provides a stable
quantitative standard for longer‐term evaluation of assays sensitiv-
ities. Secondly, the transcripts are based on uniform, defined
sequences enabling assay failures to be investigated though
comparisons of primer/probe and target sequences. Thirdly, un-
limited amounts of RNA transcripts can be generated from cDNA
clones of each target guaranteeing long term stability and reprodu-
cibility of the control materials. Fourthly, the RNA transcripts are
highly stable at ambient temperature and on repeated freeze/
thawing (Figure 2). Finally, they are noninfectious, enabling their
international distribution by ordinary post, providing considerable
cost savings, assured biological safety and simple logistics. RNA
transcripts can indeed be very easily prepared on a large scale for
little cost—in the current study, the consumable costs for laboratory
production and packaging of the transcripts was approximately €120,
while postage cost to the participating laboratories was approxi-
mately €390. This low cost enables participation in this and future
RNA transcript‐based QA exercises to be uncharged. The wide
availability and insignificant cost will facilitate the use of RNA
transcripts in the development of screening and typing capacity in
Eastern Europe, where EV detection is largely restricted to virus
isolation and neutralization assays.16
There are however also some potential disadvantages to the use of
RNA transcript controls and limitations of the study. Firstly, the RNA
controls were directly used without RNA/DNA extraction in some test
formats, so the efficiency of this step, which may be critical in clinical
sample handling, and its downstream effects on overall assay
performance was not evaluated for all assays. In practice, however,
this can be evaluated through comparison of Ct values of transcript
samples with and without an extraction step. The second potential
disadvantage of RNA transcripts was the use of carrier RNA for
stabilization. Although the concentrations used were relatively low in
molecular terms (a 5 µL aliquot used for testing contained 250 ng of
RNA), its presence could interfere with high throughput sequencing
methods that may become increasingly used for virus typing in the
F IGURE 3 Detection frequencies of EV and HPeV transcripts. Frequencies of detection of the 10 and 1000 RNA copy/5 µL dilutions of each
transcript by participant laboratories, divided by (A) transcript sequence, including detection frequencies of the HRV‐C and water negative
controls. The detection frequency of the EV‐A71 transcript was significantly higher than achieved for the other EV species (B) Assay type—in‐
house for commercially available (results for individual commercial assays are shown in Table 1), and (C) laboratory type, diagnostic or national
reference laboratory both shown separately for the EV and HPeV transcripts. P values above bars show frequency comparisons using Fisher’s
Exact Test. EV, enterovirus; HPeV, human parechovirus; HRV‐C, human rhinovirus species C
TABLE 2 Sensitivity of biofire film array assay
RNA copies/5 µL
Transcript 10 400 1000 40000
EV‐A71 N1 P2 P P
E30 ‐3 N P P
CAV21 ‐ N P P
EV‐D68 ‐ N P P
HPeV3 ‐ N N P
1Negative in assay.
2Positive in assay.
3Not done.
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future. However, the RNA amount used was well within the capacity of
current library preparation methods for Illumina and Nanopore
methods, and indeed cDNA in these concentrations may be required
for efficient template preparation. We are currently investigating the
stabilizing properties of alternative carriers such as linear acrylamide
to avoid this currently theoretical problem in the future. Finally and
more generally, RNA transcripts or cloned viral DNA sequences are
available from a relatively narrow range of viruses, typically those that
possess relatively small, non‐segmented genomes, and for which full‐
length cDNA clones representative of currently circulating strains are
available. Although RNA transcripts for EVs and HPeV used in the
current study can be readily derived from cloned sequences of a wide
range of contemporary circulating virus strains, development of
equivalent RNA (or DNA)‐based standards would be problematic or
impossible for many respiratory and enteric viruses, and for
adenoviruses, herpesviruses and other large DNA viruses with
genomes that are too large for conventional cloning strategies.
4.2 | Analytical sensitivity of EV and HPeV
detection assays
As described, the transcripts enabled assay sensitivity to be
determined in absolute RNA copy numbers, with almost all assays
able to detect 1000 copies of RNA transcripts but with more variable
detection of 10 RNA copy controls for EVs and HPeV. There are no
current statutory guidelines for EV or HPeV detection sensitivity for
diagnostic assays although previous evaluations of widely used EV
PCRs found detection limits of 10 to 50 copies for EV and
HPeV.17 This corresponds to 50 to 200 RNA copies/mL using
standard 200 μL extraction volumes of CSF. In the current study,
positive results from the low copy number EV or HPeV controls
equated to an analytical sensitivity of greater than 50 EV/HPeV RNA
genomes/mL for a standard 200 µL CSF extraction volumes. Almost
all reference laboratories achieved this sensitivity using in‐house
PCR methods, but the 10 copy control was frequently negative in
testing with commercial assays. In the case of the biofire film array
assay, the mean limit of detection for the 4 EV species was greater
than 2000‐4000 RNA copies/mL, with an even lower sensitivity for
HPeV3 (Table 2). These findings are consistent with previous
evaluations of the Biofire film assay, with reported limits of detection
for EV detection of >500 RNA copies/mL,18 and some reduction in
rates of detection of (unquantified) EV‐positive clinical samples
compared to conventional diagnostic assays.19-21
Viral loads in CSF are low, often at the limit of assay sensitivity of
PCR, so variability in assay sensitivity could substantially influence
diagnostic target detection rates in diagnostic samples. The devel-
opment of guidelines for assay sensitivity for EV and HPeV RNA
detection in CSF would be of considerable value in the future quality
control of these assays. The legislation for the use of CE‐marked
tests is driving the replacement of in‐house assays with commercial
tests, many of which offer syndromic testing with multiplexed
detection of a large range of viruses and bacteria. Although such
assays often have operational advantages as point‐of‐care tests in
emergency rooms requiring rapid results, the effects of their
potentially reduced sensitivity on their clinical utility need to be
evaluated. Validation of their performance can be challenging for
multiple analytes and existing studies typically do not include
samples with defined viral loads or identified EV species or
serotypes, nor investigation of samples that have failed detec-
tion.18-21 In the future, validation of such assays with calibrated RNA
controls is of particular value for evaluation of their performance,
particularly when the availability of control material derived from
traditional virus isolation methods becomes increasingly restricted.
F IGURE 4 Frequencies of successful
typing of EV and HPeV transcripts.
Frequencies of successful typing of the 10
and 1000 RNA copy/5 µL dilutions of EV
and HPeV transcripts divided by (A)
transcript sequence and (B) laboratory
type, diagnostic or national reference
laboratory both shown separately for the
EV and HPeV transcripts. P values above
bars show frequency comparisons using
Fisher’s Exact Test. EV, enterovirus; HPeV,
human parechovirus
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4.3 | Virus typing
In the current study, EV and HPeV typing were performed in both
reference and diagnostic laboratories (Figure 4). Although all results
reported the correct EV‐type identification and most laboratories
successfully typed the high concentration (1000 copies in 5 µL)
transcripts, fewer than 50% of either reference or diagnostic
laboratories could successfully amplify and sequence the low
concentration controls. The observed restriction in assay sensitivity
underpins the importance of obtaining multiple samples including
blood, respiratory samples and feces for EV diagnostic and typing
assays where viral loads are higher during acute infections.22-24 It is
also time to consider how EV and HPeV typing data can be centrally
collected and analyzed at the time when increasing numbers of
diagnostic laboratories are starting to introduce typing within the
hospital premises.7,16
In conclusion, effective EV and HPeV detection and type
identification are integral to clinical management, public health
surveillance and outbreak preparedness for emerging strains.
However, their genetic diversity, and often low viral loads in
diagnostic specimens places stringent demands on the analytical
sensitivity and breadth of detection and typing assays. RNA
transcripts provide the means to independently evaluate these
aspects of their performance. In the future, they can provide
objective and fixed standards needed for a more critical assessment
of the effectiveness of the numerous, newly developed and currently
largely unevaluated testing platforms for syndromic testing. We
would be delighted to provide EV, HPeV and further RNA transcript
controls for a wider range of viruses to laboratories for QA purposes
in the future.
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